期刊文献+

右旋布洛芬注射液安全药理学研究 被引量:3

Safety pharmacology research on Dexibuprofen injection
原文传递
导出
摘要 目的评价右旋布洛芬注射液对动物中枢神经系统、心血管系统及呼吸系统的影响。方法通过小鼠自主活动试验、运动协调试验和戊巴比妥钠催眠/睡眠试验,考察右旋布洛芬注射液对中枢神经系统的影响;通过对清醒Beagle犬遥测心电图、血压和呼吸指标的检测,考察右旋布洛芬注射液对心血管系统和呼吸系统的影响。结果右旋布洛芬注射液20、40、80 mg/kg剂量时对小鼠自主活动、爬杆行为均无显著影响,剂量为80 mg/kg时与戊巴比妥钠诱导的小鼠催眠/睡眠具有协同作用;剂量为10、20、40 mg/kg时对Beagle犬中枢神经系统、心血管系统和呼吸系统均没有显著影响。相同剂量条件下,右旋布洛芬注射液与布洛芬注射液比较,不良反应未见增加。结论右旋布洛芬注射液对自主活动、运动协调能力、心血管系统和呼吸系统没有显著影响,大剂量时与戊巴比妥钠诱导小鼠催眠/睡眠有协同作用。 Objective To study the effects of Dexibuprofen injection on the central nervous, cardiovascular and respiratory systemsin animals. Methods The effect of Dexibuprofen injection on central nervous system was observed by autonomic activitiesexperiment, mice concordant ability experiment and hypnotize experiment induced by pentobarbital. The effects of Dexibuprofeninjection on circulatory system and respiratory system were observed by measuring the implanted telemetry system, blood pressure,ECG~ respiratory rate and tidal volume of Beagle's dogs. Results Dexibuprofen injection (80 mg/kg) showed synergistic actionwith pentobarbital, and no significant effects on autonomic activities and concordant ability at doses of 20, 40 and 80 mg/kg in mice.Dexibuprofen injection at doses of 10, 20 and 40 mg/kg had no effect on the central nervous, cardiovagcular and respiratory systems.In the same dose, the adverse reaction of Dexibuprofen injection was not increased compared with Ibuprofen injection. ConclusionDexibuprofen injection (mice 40 mg/kg, dog 40 mg/kg) has none toxicity on cardiovascular, respiratory and central nervous systems,but at the dose of 80 mg/kg in mice has obvious effect on central nervous system.
出处 《药物评价研究》 CAS 2017年第9期1265-1269,共5页 Drug Evaluation Research
基金 山东省自主创新及成果转化专项基金资助项目(2014ZZCX02104)
关键词 右旋布洛芬注射液 安全药理学 中枢神经系统 心血管系统 呼吸系统 Dexibuprofen injection safety pharmacology central nervous system cardiovascular system respiratory system
  • 相关文献

参考文献4

二级参考文献27

  • 1缪丽燕,张华,王中,丁盛鹏.脑脊液中右旋布洛芬含量及其药动学研究[J].苏州大学学报(医学版),2004,24(3):318-320. 被引量:2
  • 2施桂英.非甾体抗炎药的合理应用[J].临床药物治疗杂志,2006,4(4):12-16. 被引量:4
  • 3蒋利,郝晶安,黄佳盛.非甾体抗炎药的安全使用[J].临床肺科杂志,2007,12(1):89-89. 被引量:8
  • 4WANGJ YANMY WANGMH.Progress in drug-induced prolongation of the QT interval syndrome .世界临床药物,2007,28(3):152-156.
  • 5SFDA. Drug Research Guidance in China [ M]. Beijing: Chinese Medical Science and Technology Press(中国医药科技出版社),2006:77-82.
  • 6ICH. ICH Harmonised Tripartite Guideline: Safety Pharmacology Studies for Human Pharmaceuticals S7A. ICH, 2000, [ 2000-11- 08]. http ://www. ich. org/LOB/media./MEDIA504, pdf.
  • 7ICH. ICH Harmonised Tripartite Guidetine: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by Human Pharmaceuticals S7B. ICH, 2005, [ 2005-05-121. http://www, ich. org/LOB/media/ MEDIA2192. pdf.
  • 8WANGSL SHENLZ QIWH etal.The focuses in the3Q validation of the safety pharmacological telemetry system .中国药学杂志,2010,45(9):55-58.
  • 9HAVERKAMP W, BREITHARDT G, CAMM A J, et aL The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology[ J]. Eur Heart J, 2000, 21(15):1216-1231.
  • 10RODEN D M. Drug-induced prolongation of the QT interval [ J]. N Engl J Med, 2004, 350(10) :1013-1022.

共引文献31

同被引文献32

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部